30 Years of Evidence

Hepatic Resection Versus Stereotactic Body Radiation Therapy Plus Transhepatic Arterial Chemoembolization for Large Hepatocellular Carcinoma: A Propensity Score Analysis

Sun J, Li WG, Wang Q, He WP, Wang HB, Han P, Zhang T, Zhang AM, Fan YZ, Sun YZ, Duan XZ | J Clin Transl Hepatol | 2021

Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial

Shi C, Li Y, Geng L, Shen W, Sui C, Dai B, Lu J, Pan M, Yang J. | Eur J Cancer | 2022

Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases

Lischalk JW, Malik RM, Collins SP, Collins BT, Matus IA, Anderson ED | Radiat Oncol. | 2016

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation

Repka MC, Aghdam N, Kataria SK, Campbell L, Suy S, Collins SP, Anderson E, Lischalk JW, Collins BT | Radiat Oncol. | 2017

Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy

Sharma A, Duijm M, Oomen-de Hoop E, Aerts JG, Verhoef C, Hoogeman M, Nuyttens JJ. | Acta Oncol | 2018

Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

Sumodhee S, Bondiau PY, Poudenx M, Cohen C, Naghavi AO, Padovani B, Maneval D, Gal J, Leysalle A, Ghalloussi H, Otto J, Doyen J | BMC Cancer | 2019

A 54 Gy in three fractions of stereotactic body radiotherapy using CyberKnife for T1b-2aN0M0 pathologically confirmed non-small cell lung cancer

Abe T, Ryuno Y, Iino M, Saito S, Aoshika T, Ohta T, Igari M, Hirai R, Kumazaki Y, Kaira K, Kagamu H, Ishida H, Noda SE, Kato S | Jpn J Clin Oncol. | 2021

Fiducial markers for stereotactic lung radiation therapy: review of the transthoracic, endovascular and endobronchial approaches

Alessio Casutt, Rémy Kinj, Esat-Mahmut Ozsahin, Christophe von Garnier, Alban Lovis | Eur Respir Rev | 2022

30 Years of Evidence